We are pleased to announce that CILcare’s Chief Scientific Officer, Sylvie Pucheu, PhD, will be at the Children Tumour Foundation’s NF Conference in Philadelphia on June 19th to give a poster presentation on the ototoxic side effects of cancer and Covid-19 treatments.
Hearing loss is a major problem caused by certain diseases such as type 2 neurofibromatosis (NF2) schwannoma and some ototoxic drugs, the chemotherapeutic cisplatin being the most ototoxic one. NF2 is a genetic condition that causes tumours to grow along nerves responsible for hearing and balance.
The aim of the study presented at this year’s NF Conference was to determine if some selected drugs under investigation for Covid-19 treatments have any effects on hearing, in comparison to the reference cisplatin. Hydroxychloroquine, Azithromycine, and Colchicine were tested and administered similarly to clinical protocol. The study showed that the ABR and DPOAE techniques are highly translational and applicable to other pathologic conditions such as NF2 schwannoma, and can be combined with histological read-outs.
Hearing impairment is a huge public health concern with a dramatically rising prevalence. Nearly half a billion people suffer from hearing loss or tinnitus today, and the number is expected to reach 2.5 billion in 2050, according to the World Health Organization. More than 200 ototoxic medications are on the market, including certain classes of antibiotics, chemotherapeutics, drugs for erectile dysfunction, and currently some tested therapies for Covid-19. These can lead to side effects ranging from sudden hearing loss and tinnitus, to balance disorders.
The NF Conference is a global event, with over 750 participants worldwide across a wide range of scientific disciplines, from research and clinical backgrounds, all focused on improving outcomes for patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis. The NF Conference is a critical forum for consensus building and advancing basic, translational, and clinical research in NF and related fields, while fostering collaborations within and beyond the NF community. Importantly, the NF Conference is a key venue for attracting and growing the number of new investigators in NF research and clinical care.
CILcare launched in January 2021 its COVIDOTOTOX research project, supported by the Occitanie Region, to contribute to the mission of finding safe treatment for Covid-19.
Learn more about the COVIDOTOTOX research project here.
Learn more about the NF Conference here.
Contact:
Marie Peytavy-Izard, Director of Marketing & Business Development
+33 (0)7 69 74 19 05
info@cilcare.com
